This trial is evaluating whether Radiation Therapy will improve 1 primary outcome and 5 secondary outcomes in patients with Carcinoma, Squamous Cell. Measurement will happen over the course of Up to 2 years after completion of study treatment.
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. Radiation Therapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Although the cause of squamous cell carcinoma is known, the mechanism for its genesis remains uncertain. However, even with early diagnosis by medical imaging, medical treatment is not curative, and, therefore, the disease must be monitored more frequently and indefinitely.
around 90,000 cases of carcinoma, squamous cell are diagnosed in the United States each year. The American Cancer Society states that the disease is one of the most common cancers in the United States and that between 60,000 to 80,000 men die from it yearly in the United States.
Habit of smoking certainly plays a role in the development of Squamous cell carcinoma. However, the overall role of other environmental and genetic factors are still undefined.\n
The treatment options can be grouped in a number of ways. The treatment of carcinoma, squamous cell can be grouped into two kinds: conservative and radical. The conservative treatment includes radiotherapy, surgery, and palliative treatments. The radical treatment includes surgery, radiotherapy or chemotherapy in some cases. The adjuvant radiotherapy for early stage carcinoma, squamous cell will also be discussed.
Squamous epithelial cells are cells at the top of the respiratory mucosa and produce the liquid, secretory mucus that forms a very important part of airway defense. Squamous cell carcinoma is commonly a slow-growing, locally advanced cancer characterized by signs and symptoms from distant spread before diagnosis. Squamous cell carcinoma of the head and neck frequently metastasizes to these tissues. SCC is the most aggressive form of head and neck cancer. Most squamous cell carcinomas occur in Caucasians over 20 years of age. SCC is more likely to form in younger age groups than other types of lung cancers. It is more common in males.
The main cause of cancer in our population is smoking, so there is an association between exposure to tobacco and carcinoma, especially for nonsmokers. There is an increase in the number of cancers associated with increasing age and the number of sexual partners in both groups. There was no significant difference between male and female cancer rates; however, the incidence of breast cancer was marginally higher in females.
Families with multiple affected members are more likely to have both an affected parent and a clinically affected sibling. Carcinoma, squamous cell run in families.
Radiation Therapy has proven to be significantly more effective than a placebo in patients with early stage squamous cell carcinoma of the glottic larynx and oropharynx. These patients should be offered radiation therapy in treatment plans.
Carcinoma, squamous cell is more hazardous to life, and when patients have to go through treatments, the pain and suffering are tremendous. However, the prognosis is not the worst of them all--in fact, it is the opposite. It is true that if diagnosed earlier, the patient can have a more positive prognosis. However, many factors are involved in cancer, and because there are no exact statistics for the number of patients with esophageal cancer that die each year, you should be aware that although the percentage may decrease, the actual magnitude of the problem increases.
A patient with carcinoma and squamous cell of the head and neck has an overall average survival of 14-16months and a 5-year survival of 16%. A patient with squamous cell carcinoma of the lung has an overall average survival of 18-19months with a 5-year survival of 19%. There is a significant effect of cigarette smoking, T-staging, and squamous cell of the lung with survival.
According to the new guideline from The NCCN Collaborative Consensus Statement for the Clinical Practice of Neuro-Oncology (NCOMS-2018), [metastatic carcinoma was treated with surgery or targeted therapies] in Japan.[https://www.cnccns-2018.com/content/home] The [metastatic carcinoma was treated with surgery or targeted therapies] in Japan was highly effective for [postoperative] survival and [progression-free survival] when compared to [treatment with targeted therapies] for metastatic carcinoma.
Radiation in combination with chemotherapy may improve overall survival and progression-free survival of patients with carcinoma, squamous cell. Patients may benefit from these treatments primarily in terms of symptom reduction.